Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.

Canada’s off-patent industry association has looked to Pharmascience and Apotex for its new chair and vice-chair.

In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.